Cefuroxime
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Cefuroxime: Hyperamylasemia
One-Sentence Summary
Cefuroxime is a beta-lactam antibiotic that inhibits bacterial cell-wall synthesis and is marketed in Canada in several single-ingredient products. The TxGNN model predicts it may be effective for hyperamylasemia, but the data compiled for this report contain no clinical trials and no publications for this prediction. The prediction is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 0.9976 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 9 of 9) |
| Number of DINs | 9 (marketed: 9) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Cefuroxime belongs to the cephalosporin class of beta-lactam antibiotics, which block bacterial cell-wall synthesis.
For hyperamylasemia (elevated serum amylase), no plausible mechanistic link to this action has been identified. Nothing about cell-wall synthesis inhibition connects to amylase regulation. It should be treated as a hypothesis-generating signal, not as a rationale for use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02344831 | AURO-CEFUROXIME | Not specified | Not specified |
| 02241638 | CEFUROXIME FOR INJECTION, USP | Not specified | Not specified |
| 02244394 | APO-CEFUROXIME | Not specified | Not specified |
| 02344823 | AURO-CEFUROXIME | Not specified | Not specified |
| 02212307 | CEFTIN | Not specified | Not specified |
Nine single-ingredient licences are currently valid; the five above are a selection.
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction screen. The ones listed here are all rated Moderate: acid-reducing agents (famotidine, ranitidine, cimetidine, nizatidine, omeprazole, rabeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole), antacids (aluminum hydroxide, calcium carbonate, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide), aminoglycosides (kanamycin, neomycin) and balsalazide.
Please also refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials or publications and no plausible mechanistic link, so the evidence level is L5.
To proceed, the following is needed:
- Mechanism-of-action data and a biological rationale connecting cefuroxime to amylase regulation
- Any clinical or preclinical study that directly examines hyperamylasemia
- Review of the Health Canada package insert for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.